Oncolytics Biotech jumps after pancreatic cancer therapy gets regulatory nod
** U.S.-listed shares of Oncolytics Biotech ONC.TO
ONCY.O rise 35.8% to $1.10 premarket
** ONCY says its pancreatic cancer therapy, pelareorep, has
received regulatory approval to continue patient enrollment
** ONCY is evaluating pelareorep in combination with
chemotherapy regimen Folfirinox and immunotherapy atezolizumab
** ONCY says it will move forward with full enrollment of 30
newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients
in the first stage
** All 5 brokerages covering the stock rate it "buy"
** ONCY fell ~31% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer